NEW YORK (GenomeWeb News) — GeneGo and Spotfire have integrated their software products for genomics, proteomics, and gene-expression analysis involved in drug development, GeneGo said today.
GeneGo’s MetaCore 4.2 is a biomarker-identification and -validation tool, and its MetaDrug platform is used to predict metabolism, toxicity, and the effects of small molecule compounds. Spotfire’s DecisionSuite, meantime, visualizes genomics data.
GeneGo said that using the integrated products will allow researchers to use DecisionSuite to analyze genomics and proteomics data and then use GeneGo’s software to perform pathway and network analysis.
Financial terms of the agreement were not released.